SW-682 in Advanced Solid Tumors

NCT06251310 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Mesothelioma, Malignant

Interventions

DRUG: SW-682
DRUG: Combination Therapy

Sponsor

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany